sever
acut
respiratori
syndrom
sar
affect
thousand
patient
countri
caus
death
juli
septemb
sarsassoci
coronaviru
sarscov
identifi
caus
agent
typic
clinic
manifest
includ
fever
cough
dyspnea
rapid
progress
pulmonari
infiltr
consolid
mean
mortal
rate
mostli
attribut
hypoxem
respiratori
failur
acut
phase
typic
patholog
find
lung
includ
mononuclear
cell
infiltr
alveolar
cell
desquam
hyalin
membran
format
mononuclear
cell
may
develop
multinucl
giant
cell
proinflammatori
cytokin
releas
alveolar
macrophag
may
play
promin
role
pathogenesi
sar
mark
elev
inflammatori
cytokin
cytokin
chemokin
monocyt
chemoattract
report
high
resolut
comput
tomographi
hrct
find
present
includ
unilater
bilater
groundglass
opac
focal
unilater
bilater
area
consolid
residu
abnorm
describ
also
discharg
hospit
day
howev
limit
inform
avail
recoveri
inflammatori
abnorm
recoveri
sar
particularli
day
beyond
current
studi
conduct
studi
examin
hrct
chang
patient
recov
acut
phase
sar
day
measur
associ
inflammatori
profil
directli
examin
bronchoalveolar
lavag
fluid
balf
also
examin
presenc
coronaviru
balf
found
persist
hrct
abnorm
lung
inflamm
day
determin
retrospect
potenti
influenc
puls
corticosteroid
therapi
process
twelv
women
men
age
year
confirm
sar
patient
treat
chang
gung
memori
hospit
taiwan
april
may
last
epidem
sar
taiwan
agre
particip
studi
patient
met
modifi
center
diseas
control
prevent
cdc
case
definit
sar
sar
confirm
either
posit
realtim
polymeras
chain
reaction
pcr
assay
elev
serum
anticoronaviru
antibodi
elisa
nasopharyngealaspir
sampl
obtain
studi
patient
exclud
common
virus
includ
influenza
virus
b
respiratori
syncyti
rsv
viru
adenoviru
parainfluenzaviru
type
use
commerciallyavail
immunofluoresc
assay
ifa
sputum
blood
cultur
perform
case
exclud
bacteri
fungal
infect
day
close
contact
rel
studi
sar
patient
serum
anticoronaviru
antibodi
measur
elisa
nine
nonsmok
healthi
volunt
women
men
age
year
without
evid
current
past
histori
pulmonari
diseas
base
histori
well
physic
chest
radiograph
bronchoscop
examin
select
control
studi
none
upper
respiratori
tract
infect
within
last
week
antibiot
medic
time
evalu
studi
protocol
approv
chang
gung
memori
hospit
ethic
committe
inform
consent
obtain
subject
treatment
sar
patient
admiss
unit
includ
broad
spectrum
antibiot
target
common
pathogen
caus
communityacquir
pneumonia
accord
current
recommend
patient
receiv
variabl
therapi
regimen
includ
oral
ribavirin
g
twice
day
day
intraven
immunoglobulin
ivig
gkg
bodi
weightday
day
puls
steroid
therapi
methylprednisolon
mg
twice
day
day
prednisolon
mgkg
bodi
weightday
day
mainten
corticosteroid
therapi
prednisolon
mg
twice
day
week
puls
steroid
therapi
administ
within
day
onset
fever
patient
depend
attend
physician
decis
irrespect
sever
present
patient
receiv
puls
steroid
therapi
given
short
cours
corticosteroid
therapi
hydrocortison
mg
timesday
day
rapid
deterior
pulmonari
infiltr
hypoxemia
mainten
steroid
therapi
prednisolon
mg
per
day
one
week
given
puls
short
cours
corticosteroid
therapi
patient
two
patient
intub
ventil
support
hypoxem
respiratori
failur
patient
underw
hrct
bal
day
onset
diseas
hrct
perform
collim
section
reconstruct
use
high
spatial
frequenc
algorithm
use
gener
electr
medic
system
milwauke
wi
hrct
protocol
consist
thin
section
obtain
chest
supin
posit
without
use
intraven
contrast
medium
hrct
find
previous
describ
categor
predomin
pattern
normal
attenu
ground
glass
opacif
hazi
area
increas
attenu
without
obscur
underli
vessel
consolid
homogen
opacif
parenchyma
obscur
underli
vessel
reticular
pattern
mix
pattern
combin
consolid
ground
glass
opac
reticular
opac
presenc
architectur
distort
groundglass
attenu
traction
bronchiolectasi
bronchiectasi
honeycomb
pattern
extent
involv
abnorm
assess
independ
three
zone
upper
carina
middl
carina
inferior
pulmonari
vein
lower
inferior
pulmonari
vein
lung
zone
total
lung
zone
assign
score
modifi
previous
describ
base
follow
involv
involv
involv
involv
involv
summat
score
provid
overal
lung
involv
maxim
ct
score
grade
patient
chest
radiograph
hrct
consensu
two
observ
blind
clinic
inform
patient
bal
perform
studi
subject
use
six
aliquot
ml
salin
solut
describ
previous
briefli
steril
salin
solut
introduc
subsegment
bronchu
sever
involv
lobe
bal
fluid
retriev
centrifug
supernat
store
analysi
cell
pellet
wash
resuspend
cell
per
ml
cell
viabil
differenti
cell
count
determin
total
rna
dna
extract
nasopharyng
aspir
cell
retriev
bal
viral
rna
minikit
qiamp
dna
minikit
qiagen
hilden
germani
reversetranscriptas
rt
pcr
done
influenza
adenoviru
human
metapneumoviru
sarscov
describ
previous
bal
cell
simultan
stain
fluorescein
isothiocyan
phycoerythrinconjug
monoclon
antibodi
beckon
dickinson
mountain
view
ca
accord
manufactur
protocol
identifi
proport
lymphocyt
cell
b
cell
natur
killer
nk
cell
subpopul
respect
rel
ratio
cell
assay
dualcolor
analysi
data
acquir
analyz
use
becton
dickinson
bd
lysi
ii
cytometr
bead
array
cba
softwar
san
jose
ca
level
cytokin
chemokin
bal
fluid
assay
use
becton
dickinson
bd
cytometr
bead
cba
bd
bioscienc
san
jose
ca
accord
manufactur
instruct
antibodi
pharmoingen
san
diego
ca
one
five
cytokin
human
chemokin
kit
bd
bioscienc
six
cytokin
human
inflamm
kit
bd
bioscienc
commerci
avail
elisa
r
system
minneapoli
use
measur
growth
factor
egf
use
previouslydescrib
method
viru
detect
electron
microscopi
cell
retriev
bal
sar
patient
normal
subject
centrifug
cell
pellet
fix
embed
stain
tannic
acid
uranyl
acet
ultrathin
section
cut
eponembed
block
stain
uranyl
acet
lead
citrat
examin
use
transmiss
electron
microscop
tem
hitachi
tokyo
japan
data
express
mean
sem
baselin
characterist
diseas
laboratori
variabl
group
compar
use
twotail
student
ttest
chisquar
test
respect
spearman
rank
test
use
determin
correl
hrct
score
cell
number
subpopul
well
ratio
univari
analys
determin
factor
respons
persist
hrct
abnorm
primarili
use
select
variabl
base
p
valu
signific
variabl
enter
stepwis
logist
regress
analysi
determin
net
effect
predictor
control
other
pvalu
consid
statist
signific
analysi
perform
use
spss
softwar
version
chicago
il
usa
patient
confirm
diagnosi
sar
admit
studi
period
sixteen
patient
receiv
intub
ventilatori
support
respiratori
failur
three
die
intract
hypoxem
respiratori
failur
twentyf
patient
recov
subsequ
discharg
hospit
patient
relaps
either
fever
new
pulmonari
infiltr
discharg
hospit
twenti
patient
randomli
select
protocol
twelv
agre
particip
patient
compli
protocol
day
day
patient
agre
repeat
hrct
patient
followup
bronchoscopi
day
commonest
symptom
sar
patient
gener
weak
patient
exert
dyspnea
patient
joint
pain
patient
partial
hair
loss
patient
day
sar
patient
well
without
abovedescrib
symptom
detect
sarscov
antibodi
sera
close
contact
rel
studi
patient
even
though
sar
patient
isol
discharg
hospit
close
rel
day
sar
patient
found
hrct
abnorm
total
lung
field
score
zero
one
ground
glass
attenu
found
total
lung
field
anoth
consolid
total
lung
field
sar
patient
hrct
abnorm
lung
field
mean
involv
total
lung
field
tabl
promin
hrct
find
patient
groundglass
attenu
total
abnorm
hrct
consolid
total
abnorm
hrct
honeycomb
bronchiectat
chang
found
sar
patient
high
hrct
score
total
abnorm
hrct
seven
patient
found
normal
followup
hrct
day
tabl
figur
two
patient
persist
high
hrct
score
tabl
one
high
hrct
score
day
refus
followup
hrct
residu
abnorm
hrct
day
relat
clinic
cours
univari
analysi
identifi
factor
associ
residu
abnorm
hrct
greater
proport
patient
receiv
puls
steroid
therapi
patient
high
hrct
score
tabl
contrast
none
patient
low
hrct
score
receiv
puls
steroid
therapi
tabl
signific
differ
therapi
includ
mainten
short
cours
corticosteroid
therapi
ivig
ribavirin
patient
high
hrct
score
low
hrct
score
tabl
patient
high
hrct
score
significantli
longer
cours
fever
higher
serum
sarscov
antibodi
titer
compar
patient
low
hrct
score
tabl
day
compar
normal
subject
signific
increas
total
cell
count
bal
fluid
sar
patient
tabl
signific
increas
alveolar
macrophag
lymphocyt
proport
cell
increas
greater
extent
cell
lead
signific
decreas
ratio
tabl
also
signific
increas
proport
nk
cell
sar
patient
tabl
signific
differ
b
lymphocyt
sar
patient
low
high
hrct
score
normal
subject
hrct
score
highli
correl
cell
count
total
lymphocyt
cell
invers
relat
ratio
figur
day
cellular
profil
bal
fluid
sar
patient
significantli
improv
compar
day
near
normal
tabl
day
sar
patient
significantli
higher
level
chemokin
rant
tabl
proinflammatori
cytokin
howev
growth
factor
transform
growth
epiderm
growth
factor
egf
insulinlik
growth
increas
tabl
enrol
patient
serolog
evid
recent
infect
sarscov
seven
viral
rna
detect
sampl
taken
nasopharyng
aspir
stool
howev
viral
rna
detect
stool
nasopharyng
aspir
sar
patient
day
healthi
control
evid
sarscov
antibodi
rna
serum
respiratori
tract
detect
common
virus
includ
influenza
virus
b
rsv
viru
adenoviru
human
metapneumoviru
parainfluenzaviru
type
use
ifa
nasopharyng
aspir
use
rtpcr
assay
cell
retriev
bal
day
serolog
studi
clamydia
mycoplasma
legionella
neg
subject
day
em
examin
bal
fluid
reveal
mani
coronavirusinfect
alveolar
macrophag
intracellular
viral
particl
patient
figur
tabl
patient
high
hrct
scan
score
coronaviru
infect
cell
detect
sar
patient
low
hrct
score
normal
subject
tabl
rtpcr
amplif
coronaviru
nucleic
acid
posit
patient
high
hrct
score
none
patient
low
hrct
score
normal
subject
day
em
examin
detect
coronavirusinfect
cell
sar
patient
viral
inclus
found
day
tabl
one
patient
persist
high
hrct
score
case
refus
followup
bal
studi
day
studi
perform
last
epidem
sar
taiwan
number
patient
recruit
limit
epidem
recur
case
sar
taiwan
abl
increas
number
patient
studi
despit
rel
low
number
observ
indic
persist
import
inflammatori
radiolog
abnorm
patient
recov
acut
sar
day
ill
chang
groundglass
orand
consolid
abnorm
may
overlook
examin
plain
chest
radiograph
bal
fluid
examin
perform
first
time
recov
sar
patient
confirm
presenc
ongo
activ
inflammatori
process
patient
increas
macrophag
nk
cell
cell
augment
level
chemokin
proinflammatori
cytokin
inflammatori
respons
may
elicit
persist
presenc
coronaviru
alveolar
macrophag
sinc
patient
highest
hrct
chang
coronavirus
present
evid
bacteri
viral
infect
patient
viral
diseas
character
develop
specif
infiltr
consist
predominantli
mononuclear
leukocyt
neutrophil
absent
strike
featur
alveolar
inflamm
patient
increas
number
alveolar
macrophag
lymphocyt
nk
cell
strike
decreas
ratio
hrct
score
highli
correl
lymphocyt
number
subpopul
invers
relat
ratio
cell
may
act
cytotox
cell
key
effector
viru
clearanc
concurr
increas
cell
may
promot
clonal
expans
virusspecif
cell
essenti
maintain
continu
cell
surveil
effector
capac
exposur
monocyt
macrophag
virus
caus
releas
proinflammatori
cytokin
chemokin
well
member
ccchemokin
subfamili
rant
preferenti
attract
monocyt
lymphocyt
cxcchemokin
major
neutrophil
chemoattract
migcxc
chemokin
ligand
cxcl
induc
elrneg
cxc
chemokin
potent
chemoattract
mononuclear
cell
specif
activ
lymphocyt
nk
cell
report
demonstr
elev
level
rant
bal
fluid
sar
patient
compar
normal
subject
increas
secret
may
deriv
virusinfect
macrophag
cell
cytokin
may
promot
tlymphocyt
extravas
macrophag
activ
process
may
suffici
recruit
activ
mononuclear
cell
virusinfect
lung
increas
level
rant
bal
fluid
sar
patient
may
respons
gener
mononuclear
infiltr
observ
coronaviru
infect
mig
whose
level
also
increas
sar
patient
recruit
monocyt
macrophag
nk
cell
activ
rest
lymphocyt
although
increas
level
bal
fluid
sar
patient
number
neutrophil
balf
spars
absenc
neutrophil
infiltr
influenza
viru
respiratori
syncyti
virus
rsv
infect
attribut
suppress
neutrophil
attract
cxcchemokin
induct
howev
product
induc
measl
viru
infect
fibroblast
influenza
viru
rsv
rhinoviru
pulmonari
epitheli
cell
reason
lack
neutrophil
recruit
respons
elev
level
sar
patient
known
deserv
investig
despit
presenc
viru
day
patient
alreadi
discharg
hospit
patient
infecti
none
close
contact
rel
develop
detect
sarscov
antibodi
sera
hrct
clinic
cours
day
ill
suggest
evid
pulmonari
fibrosi
sar
patient
accord
low
level
cytokin
growth
factor
respons
tissu
repair
fibrosi
egf
detect
bal
fluid
howev
evid
fibrosi
hrct
obtain
hrct
scan
particularli
patient
sever
diseas
acut
phase
sar
use
corticosteroid
togeth
ribavirin
report
confer
clinic
benefit
although
random
clinic
trial
support
clinic
efficaci
avail
puls
steroid
therapi
report
lead
less
oxygen
requir
better
radiograph
outcom
less
likelihood
requir
rescu
puls
steroid
therapi
counterpart
howev
corticosteroid
shown
increas
mortal
pneumovirusinfect
mice
acceler
replic
viru
puls
steroid
therapi
also
report
associ
residu
abnorm
hrct
sar
patient
discharg
hospit
current
retrospect
nonrandom
seri
puls
steroid
therapi
appear
associ
delay
resolut
pneumon
plan
prospect
futur
studi
investig
effect
puls
steroid
therapi
case
futur
outbreak
sar
issu
extrem
import
outcom
sar
conclus
proport
recov
sar
patient
delay
resolut
pneumon
delay
clearanc
coronaviru
alveolar
space
day
associ
persist
inflammatori
respons
character
macrophag
cell
particularli
cell
nk
cell
increas
cytokin
chemokin
host
inflammatori
respons
sarscov
infect
may
contribut
persist
hrct
abnorm
recoveri
phase
sar
hand
found
evid
pulmonari
fibrosi
sar
patient
recoveri
day
mani
abnorm
disappear
patient
recov
sar
need
follow
least
month
infect
